Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Orthopaedic and Trauma Surgery
Published in: Archives of Orthopaedic and Trauma Surgery 11/2009

01-11-2009 | Orthopaedic Surgery

Barriers to the optimal use of anticoagulants after orthopaedic surgery

Author: L. C. Borris

Published in: Archives of Orthopaedic and Trauma Surgery | Issue 11/2009

Login to get access

Abstract

Venous thromboembolism (VTE) and the consequent morbidity and mortality associated with this condition continue to be a problem following orthopaedic surgery. The vast majority of patients undergoing orthopaedic surgery receive some form of thromboprophylaxis. However, the use of inappropriate thromboprophylaxis is an important factor which may explain why the clinical burden of VTE is still considerable. Barriers to the use of appropriate thromboprophylaxis include the belief by some surgeons that pharmacological thromboprophylaxis increases the risk of bleeding and the asymptomatic nature of deep vein thrombosis. In addition, in patients at risk of VTE, thromboprophylaxis should be given beyond the standard duration recommended in international or national guidelines, and many surgeons have concerns about adherence and adverse events in the outpatient setting. Furthermore, currently available anticoagulants have drawbacks, including the need for monitoring, or a subcutaneous route of administration. The introduction and implementation of multi-faceted and integrated approaches to thromboprophylaxis could improve adherence with current guidelines, extend appropriate thromboprophylaxis according to risk factors, and improve patient outcomes in this setting. In addition, the development of new anticoagulants with more convenient administration regimens and no need for monitoring may help to achieve these objectives.
Literature
1.
Anderson FA Jr, White K (2002) Prolonged prophylaxis in orthopedic surgery: insights from the United States. Semin Thromb Hemost 28(Suppl 3):43–46PubMedCrossRef
2.
Arnold DM, Kahn SR, Shrier I (2001) Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 120:1964–1971PubMedCrossRef
3.
Aujesky D, Guignard E, Pannatier A et al (2002) Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med 17:788–791PubMedCrossRef
4.
Bergqvist D (1993) Long-term prophylaxis following orthopedic surgery. Haemostasis 23(Suppl 1):27–31PubMed
5.
Bergqvist D, Jonsson B (1999) Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2:288–294PubMedCrossRef
6.
Blackburn J, Schumock G, Bauman J (2005) Barriers to appropriate anticoagulation with warfarin in orthopedic surgery. J Thromb Haemost 3(Suppl 1):PO430
7.
Borris LC, Breindahl M, Ryge C et al (2007) Prothrombin fragment 1+2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty. Thromb Res 121:369–376PubMedCrossRef
8.
Brenkel IJ, Cook RE (2003) Thromboprophylaxis in patients undergoing total hip replacement. Hosp Med 64:281–287PubMed
9.
Brenkel IJ, Hyers TM (2004) Thromboprophylaxis in patients undergoing hip replacement: a survey of British orthopaedic surgeons. J Bone Joint Surg Br 87(Suppl III):277
10.
Caprini JA, Hyers TM (2006) Compliance with antithrombotic guidelines. Manag Care 15:49–60, 66
11.
Cohen AT, Alikhan R, Arcelus JI et al (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 94:750–759PubMed
12.
Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394PubMedCrossRef
13.
Cohn SL, Adekile A, Mahabir V (2006) Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention. J Hosp Med 1:331–338PubMedCrossRef
14.
Dahl OE (1999) Mechanisms of hypercoagulability. Thromb Haemost 82:902–906PubMed
15.
Dahl OE (2000) Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis 30(Suppl 2):101–105PubMed
16.
Dahl OE (2004) Orthopaedic surgery as a model for drug development in thrombosis. Drugs 64(Suppl 1):17–25PubMedCrossRef
17.
Eriksson BI, Quinlan DJ (2006) Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 66:1411–1429PubMedCrossRef
18.
Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef
19.
Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S–400SPubMedCrossRef
20.
Gross M, Anderson DR, Nagpal S et al (1999) Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg 42:457–461PubMed
21.
Haas S (2003) Medical indications and considerations for future clinical decision making. Thromb Res 109:S31PubMedCrossRef
22.
Haas S, Schellong S (2007) New anticoagulants: from bench to bedside. Hamostaseologie 27:41–47PubMed
23.
Kakkar VV, Cohen AT, Edmonson RA et al (1993) Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 341:259–265PubMedCrossRef
24.
Kakkar AK, Levine M, Pinedo HM et al (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8:381–388PubMedCrossRef
25.
Kakkar AK, Davidson BL, Haas SK (2004) Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2:221–227PubMedCrossRef
26.
Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef
27.
Koch A, Ziegler S, Breitschwerdt H et al (2001) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 102:295–309PubMedCrossRef
28.
Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2886PubMedCrossRef
29.
Learhinan ER, Alderman CP (2003) Venous thromboembolism prophylaxis in a South Australian teaching hospital. Ann Pharmacother 37:1398–1402PubMedCrossRef
30.
Levine MN, Raskob G, Beyth RJ et al (2004) Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:287S–310SPubMedCrossRef
31.
Lieberman JR, Hsu WK (2005) Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 87:2097–2112PubMedCrossRef
32.
Mismetti P, Laporte S, Darmon JY et al (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913–930PubMedCrossRef
33.
34.
Salvati EA, Pellegrini VD Jr, Sharrock NE et al (2000) Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am 82:252–270PubMed
35.
Scaglione L, Piobbici M, Pagano E et al (2005) Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows. Haematologica 90:678–684PubMed
36.
Schunemann HJ, Cook D, Grimshaw J et al (2004) Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:688S–696SPubMedCrossRef
37.
Select Committee on Health of the United Kingsom (2005) Second Report. Hansard
38.
Tapson VF, Goldhaber SZ (2003) Failure to provide prophylaxis for deep vein thrombosis: results from the DVT-Free registry. Blood 102:322a
39.
Tooher R, Middleton P, Pham C et al (2005) A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 241:397–415PubMedCrossRef
40.
Turpie AG (2007) Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238–1247PubMedCrossRef
41.
Vallano A, Arnau De Bolos JM et al (2004) Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thromb J 2:3PubMedCrossRef
42.
Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing surgery (2007) National Institute of Health and Clinical Excellence Guideline 46
43.
Walker N, Rodgers A, Gray H (2002) Changing patterns of pharmacological thromboprophylaxis use by orthopaedic surgeons in New Zealand. ANZ J Surg 72:335–338PubMedCrossRef
44.
Wan S, Ting J, Olsen A et al (2003) Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. ANZ J Surg 73:826–829PubMedCrossRef
45.
Warwick D, Friedman RJ, Agnelli G et al (2007) Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 89:799–807PubMedCrossRef
46.
Zaw HM, Osborne IC, Pettit PN et al (2002) Risk factors for venous thromboembolism in orthopedic surgery. Isr Med Assoc J 4:1040–1042PubMed
Metadata
Title
Barriers to the optimal use of anticoagulants after orthopaedic surgery
Author
L. C. Borris
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Archives of Orthopaedic and Trauma Surgery / Issue 11/2009
Print ISSN: 0936-8051
Electronic ISSN: 1434-3916
DOI
https://doi.org/10.1007/s00402-008-0765-9

Other articles of this Issue 11/2009

Archives of Orthopaedic and Trauma Surgery 11/2009 Go to the issue

Orthopaedic Surgery

Infections after high tibial open wedge osteotomy: a case control study

Orthopaedic Surgery

Our clinical experience on calcaneal bone cysts: 36 cysts in 33 patients

Letter to the Editor

Osteonecrosis of femoral head and hyperbaric oxygen therapy

Orthopaedic Surgery

Daptomycin in bone and joint infections: a review of the literature

Orthopaedic Surgery

Cervical and upper thoracic screwing for spinal fusion: strategy for its safe insertion to avoid major complications

Basic Science

The effect of platelet-rich plasma gel in the early phase of patellar tendon healing